GV20 Therapeutics - Crunchbase Company Profile & Funding

Q: Where is GV20 Therapeutics's headquarters?

GV20 Therapeutics is located in Shanghai, Shanghai, China.

Q: Who invested in GV20 Therapeutics?

GV20 Therapeutics has 8 investors including Mitsubishi Tanabe Pharma And Watson Capital Partners.

Q: When was the last funding round for GV20 Therapeutics?

GV20 Therapeutics closed its last funding round on obfuscated from a Corporate Round round.

Q: How much funding has GV20 Therapeutics raised to date?

GV20 Therapeutics has raised obfuscated.

Overview

GV20 Therapeutics

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About GV20 Therapeutics

CB Rank

57474

GV20 Therapeutics is a healthcare company committed to developing better cancer drugs at a faster and lower cost.

Founded

obfuscation

Private

Corporate Round

Shanghai, Shanghai, China

11-50

bioxbh.com/

Big Data

Biotechnology

Health Care

Funding Rounds

Corporate Round

OBF

obfuscation

Series B

OBF

obfuscation

Angel

OBF

obfuscation

Key People

Dr. Wei Yang: Chief Scientific Officer
Shirley Liu: CEO and Co-founder

Details

Legal Name

Xunbaihui Biotechnology Co., Ltd.

Also Known As

Xunbaihui Biotechnology, 寻百会生物

Operating Status

Active

Company Type

For Profit

Founders

Shirley Liu, Tengfei Ted Xiao

About the Company

GV20 Therapeutics is a cancer immunology drug discovery and development company that uses high throughput functional genomics and AI approaches to identify novel cancer immunology drug targets and discover and develop effective antibody drugs. The proprietary antibody drug discovery engine developed by GV20 Therapeutics contributes to the

development of a strong portfolio of immuno-oncology antibody drug candidates against novel and difficult targets.

Contact Email

xbhhr@bioxbh.com

Predictions & Insights

Growth Insight

See this Growth Insight

GV20 Therapeutics is

Lorem

to be growing

Top Contributing Factors

Recently Raised Funding

Growth Prediction

See this Growth Prediction

Top Contributing Factors

Runway Speculation

Products & Services

GV20-0251

A first-in-class, fully human, Fc-attenuated IgG1 monoclonal antibody targeting the novel immune checkpoint IGSF8, currently in Phase I clinical trial for advanced solid tumors.

STEAD platform

An integrated platform combining AI, genomics, and disease biology for simultaneous target evaluation and antibody discovery, aimed at identifying novel drug targets and creating next-generation antibody therapeutics.

Research & Development

GV20 Therapeutics is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated

...

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Corporate Round - GV20 Therapeutics	1	obfuscated obfuscation	Mitsubishi Tanabe Pharma	Corporate Round
obfuscated obfuscation	Corporate Round - GV20 Therapeutics	1	obfuscated obfuscation	Mitsubishi Tanabe Pharma	Corporate Round
obfuscated obfuscation	Corporate Round - GV20 Therapeutics	1	obfuscated obfuscation	Mitsubishi Tanabe Pharma	Corporate Round
obfuscated obfuscation	Corporate Round - GV20 Therapeutics	1	obfuscated obfuscation	Mitsubishi Tanabe Pharma	Corporate Round
obfuscated obfuscation	Corporate Round - GV20 Therapeutics	1	obfuscated obfuscation	Mitsubishi Tanabe Pharma	Corporate Round

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Corporate Round - GV20 Therapeutics	1	obfuscated obfuscation	Mitsubishi Tanabe Pharma	Corporate Round
obfuscated obfuscation	Corporate Round - GV20 Therapeutics	1	obfuscated obfuscation	Mitsubishi Tanabe Pharma	Corporate Round
obfuscated obfuscation	Corporate Round - GV20 Therapeutics	1	obfuscated obfuscation	Mitsubishi Tanabe Pharma	Corporate Round
obfuscated obfuscation	Corporate Round - GV20 Therapeutics	1	obfuscated obfuscation	Mitsubishi Tanabe Pharma	Corporate Round
obfuscated obfuscation	Corporate Round - GV20 Therapeutics	1	obfuscated obfuscation	Mitsubishi Tanabe Pharma	Corporate Round

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
Mitsubishi Tanabe Pharma	Yes	Corporate Round - GV20 Therapeutics	—
Mitsubishi Tanabe Pharma	Yes	Corporate Round - GV20 Therapeutics	—
Mitsubishi Tanabe Pharma	Yes	Corporate Round - GV20 Therapeutics	—
Mitsubishi Tanabe Pharma	Yes	Corporate Round - GV20 Therapeutics	—
Mitsubishi Tanabe Pharma	Yes	Corporate Round - GV20 Therapeutics	—